Clinical Trials
50 trialsCytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
M.D. Anderson Cancer Center
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
National Cancer Institute (NCI)
Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma
National Cancer Institute (NCI)
Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial
National Cancer Institute (NCI)
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
iPRRT
Weill Medical College of Cornell University
NeoMatryx
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
I-MAT
Melanoma and Skin Cancer Trials Limited
Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers
Ohio State University Comprehensive Cancer Center
MCC
Abramson Cancer Center at Penn Medicine
Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma
Melanoma Institute Australia
TIL Therapy in cSCC and MCC
Dana-Farber Cancer Institute
TRICK-MCC
University of Washington
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Hypofractionated Radiation Therapy for Merkel Cell Carcinoma
M.D. Anderson Cancer Center
MERCURY
Gruppo Oncologico del Nord-Ovest
A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
Regeneron Pharmaceuticals
A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
Incyte Corporation
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
University of Pittsburgh
ADMEC-O
University Hospital, Essen
A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Memorial Sloan Kettering Cancer Center
QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy
ImmunityBio, Inc.
iPREDICT
ImaginAb, Inc.
MERKLIN2
4SC AG
QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)
ImmunityBio, Inc.
Avelumab in Participants With Merkel Cell Carcinoma (JAVELIN Merkel 200)
EMD Serono
PANDORA
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
IntriNSiC
Philogen S.p.A.
Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer
National Cancer Institute (NCI)
MCC
OncoSec Medical Incorporated
Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma
Dana-Farber Cancer Institute
PUTNET
Excel Diagnostics and Nuclear Oncology Center
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
MP3
Trans Tasman Radiation Oncology Group
Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)
4SC AG
Palliative RT & Anti-PD-1/PD-L1 Checkpoint Blockade in Metastatic Merkel Cell Carcinoma
Stanford University
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma
National Institutes of Health Clinical Center (CC)
F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma
Philogen S.p.A.
PHRC-Merkel
University Hospital, Grenoble
Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy
National Cancer Institute (NCI)
Irinotecan in Treating Patients With Advanced Neuroendocrine Tumors
Memorial Sloan Kettering Cancer Center
Oblimersen in Treating Patients With Merkel Cell Carcinoma
National Cancer Institute (NCI)
S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
National Cancer Institute (NCI)
S9716: Combination Chemotherapy in Treating Patients With Merkel Cell Cancer
SWOG Cancer Research Network